ArticleCytotherapy2026

A phase 1b study on the safety of Wharton's jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease.

William Wesson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.